

Maya H Buch

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6684185/maya-h-buch-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

7,818
citations

34
h-index

87
g-index

155
ext. papers

10,205
ext. citations

5.4
avg, IF

5.67
L-index

#	Paper	IF	Citations
130	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.. <i>Journal of Scleroderma and Related Disorders</i> , 2022 , 7, 24-32	2.3	5
129	Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	1
128	RA-MAP, molecular immunological landscapes in early rheumatoid arthritis and healthy vaccine recipients.. <i>Scientific Data</i> , 2022 , 9, 196	8.2	0
127	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. <i>Rheumatology</i> , 2021 , 60, 3209-3221	3.9	8
126	Symptom experience of limited cutaneous systemic sclerosis from the Patients' perspective: A qualitative study. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 52, 151926-151926	5.3	1
125	Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. <i>Rheumatology</i> , 2021 , 60, 4048-4054	3.9	7
124	Using cardiovascular magnetic resonance to define mechanisms of comorbidity and to measure the effect of biological therapy: the CADERA observational study. <i>Efficacy and Mechanism Evaluation</i> , 2021 , 8, 1-42	1.7	
123	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
122	The PREdictor of MALnutrition in Systemic Sclerosis (PREMASS) Score: A Combined Index to Predict 12 Months Onset of Malnutrition in Systemic Sclerosis. <i>Frontiers in Medicine</i> , 2021 , 8, 651748	4.9	1
121	Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol. <i>BMJ Open</i> , 2021 , 11, e044765	3	2
120	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021 , 6, 66-76	2.3	2
119	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 31-35	2.4	61
118	Cardiac magnetic resonance imaging for the detection of myocardial involvement in granulomatosis with polyangiitis. <i>International Journal of Cardiovascular Imaging</i> , 2021 , 37, 1053-1062	2.5	1
117	Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 17-33	8.1	29
116	Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis. <i>Rheumatology</i> , 2021 , 60, 2934-2945	3.9	4
115	Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing. <i>Rheumatology</i> , 2021 , 60, 1216-1225	3.9	3
114	Changes in the pharmacological management of rheumatoid arthritis over two decades. <i>Rheumatology</i> , 2021 , 60, 4141-4151	3.9	2

113	Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. <i>Lancet, The</i> , 2021 , 397, 305-317	40	42
112	Response to: Correspondence on Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naive, early rheumatoid arthritis by Georgiadis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	
111	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021 ,	2.4	6
110	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 499-518	27.4	154
109	Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021 , 7,	5.9	2
108	Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis. <i>Rheumatology</i> , 2021 , 60, 3679-3688	3.9	3
107	Syndemics & syndemogenesis in COVID-19 and rheumatic and musculoskeletal diseases: old challenges, new era. <i>Rheumatology</i> , 2021 , 60, 2040-2045	3.9	6
106	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020 , 80, 849-857	12.1	10
105	Feasibility of MRI based extracellular volume fraction and partition coefficient measurements in thigh muscle. <i>British Journal of Radiology</i> , 2020 , 93, 20190931	3.4	0
104	Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 464-471	2.4	10
103	Cardiovascular MRI evidence of reduced systolic function and reduced LV mass in rheumatoid arthritis: impact of disease phenotype. <i>International Journal of Cardiovascular Imaging</i> , 2020 , 36, 491-501 ^{2.5}		4
102	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 685-699 ^{2.4}		851
101	Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study. <i>RMD Open</i> , 2020 , 6,	5.9	9
100	The perpetual sword of Damocles: Cardiac involvement in systemic sclerosis and the role of non-invasive imaging modalities in medical decision making. <i>European Journal of Rheumatology</i> , 2020 , 7, S203-S211	1.7	4
99	Abnormal electrophysiological testing associates with future incidental significant arrhythmia in scleroderma. <i>Rheumatology</i> , 2020 , 59, 899-900	3.9	4
98	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020 , 6,	5.9	5
97	Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease. <i>RMD Open</i> , 2020 , 6,	5.9	9
96	Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e140	2.4	1

95	Transforming clinical trials in rheumatology: towards patient-centric precision medicine. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 590-599	8.1	15
94	Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1414-1422	2.4	14
93	Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1812-1823	9.5	40
92	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 130	5.7	10
91	089 Single centre cohort of refractory rheumatoid arthritis also identifies a rare subgroup of multiple targeted therapy class non-response. <i>Rheumatology</i> , 2019 , 58,	3.9	1
90	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 1684-1686	3.9	3
89	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , 2019 ,	3.9	21
88	First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1138-1140	2.4	5
87	Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. <i>Frontiers in Medicine</i> , 2019 , 6, 45	4.9	23
86	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1553-1570	9.5	31
85	Response to Correspondence to viewpoint Defining refractory rheumatoid arthritis by Buch by Roodenrijs. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e106	2.4	3
84	Normal values and test-retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle. <i>British Journal of Radiology</i> , 2019 , 92, 20190143	3.4	8
83	Incidental significant arrhythmia in scleroderma associates with cardiac magnetic resonance measure of fibrosis and hs-TnI and NT-proBNP. <i>Rheumatology</i> , 2019 , 58, 1221-1226	3.9	17
82	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2019 , 58, 254-259	3.9	7
81	Can switching to abatacept therapy in patients with rheumatoid arthritis on background methotrexate reverse TNF-inhibitor-induced antinuclear autoantibody/double-stranded DNA autoantibody conversion? An analysis of the AMPLE and ATTEST trials. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 127-132	2.2	1
80	A Multicenter Study of the Validity and Reliability of Responses to Hand Cold Challenge as Measured by Laser Speckle Contrast Imaging and Thermography: Outcome Measures for Systemic Sclerosis-Related Raynaud Phenomenon. <i>Arthritis and Rheumatology</i> , 2018 , 70, 903-911	9.5	39
79	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 563-570	2.4	31
78	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018 , 57, 370-381	3.9	36

77	Defining refractory rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 966-969	2.4	58
76	GP2015 as a promising therapy for rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2018 , 18, 477-481	5.4	2
75	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1405-1412	2.4	63
74	Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 697-708	4.1	8
73	Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-280	4.4	7
72	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018 , 4, e000757	5.9	18
71	Carotid artery volumetric measures associate with clinical ten-year cardiovascular (CV) risk scores and individual traditional CV risk factors in rheumatoid arthritis; a carotid-MRI feasibility study. <i>Arthritis Research and Therapy</i> , 2018 , 20, 266	5.7	4
70	Patient-reported outcomes and safety in patients undergoing synovial biopsy: comparison of ultrasound-guided needle biopsy, ultrasound-guided portal and forceps and arthroscopic-guided synovial biopsy techniques in five centres across Europe. <i>RMD Open</i> , 2018 , 4, e000799	5.9	19
69	Drug-Induced Interstitial Lung Disease: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	117
68	The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1169-1175	2.4	27
67	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1207-1218	2.4	71
66	Ultrasound-detectable grey scale synovitis predicts future fulfilment of the 2010 ACR/EULAR RA classification criteria in patients with new-onset undifferentiated arthritis. <i>RMD Open</i> , 2017 , 3, e000394	5.9	16
65	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 503-510	8.1	37
64	Abatacept reduces disease activity and ultrasound power Doppler in ACPA-negative undifferentiated arthritis: a proof-of-concept clinical and imaging study. <i>Rheumatology</i> , 2017 , 56, 58-67	3.9	5
63	Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2017 , 19, 239	5.7	30
62	The Relationship Between Synovial Pathobiology and Magnetic Resonance Imaging Abnormalities in Rheumatoid Arthritis: A Systematic Review. <i>Journal of Rheumatology</i> , 2017 , 44, 1311-1324	4.1	7
61	Synovial tissue research: a state-of-the-art review. <i>Nature Reviews Rheumatology</i> , 2017 , 13, 463-475	8.1	107
60	Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis. <i>Rheumatology</i> , 2017 , 56, 912-921	3.9	47

59	Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2017 , 19, 288	5.7	27
58	Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group. <i>Rheumatology</i> , 2017 , 56, 882-895	3.9	13
57	Absence of Scleroderma pattern at nail fold capillaroscopy valuable in the exclusion of Scleroderma in unselected patients with Raynaud's Phenomenon. <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 342	2.8	11
56	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. <i>Rheumatology</i> , 2016 , 55, 2181-2190	3.9	18
55	Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?. <i>Rheumatology</i> , 2016 , 55, 2273-2275	3.9	1
54	BSR and BHPR guideline for the treatment of systemic sclerosis. <i>Rheumatology</i> , 2016 , 55, 1906-10	3.9	97
53	Discordance between the predictors of clinical and imaging remission in patients with early rheumatoid arthritis in clinical practice: implications for the use of ultrasound within a treatment-to-target strategy. <i>Rheumatology</i> , 2016 , 55, 1177-87	3.9	27
52	A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). <i>BMC Musculoskeletal Disorders</i> , 2016 , 17, 61	2.8	8
51	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 963-9	2.4	27
50	B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use. <i>Current Rheumatology Reports</i> , 2015 , 17, 65	4.9	11
49	An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1195-201	2.4	34
48	Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 516-28	2.4	224
47	Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 529-35	2.4	266
46	Sustained remission with etanercept tapering in early rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2014 , 371, 1781-92	59.2	141
45	The enhanced liver fibrosis test: a clinical grade, validated serum test, biomarker of overall fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 420-7	2.4	28
44	Response to Dr Bredemeier's letter. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, e34	2.4	
43	Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 510-5	2.4	106
42	Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 909-12	2.4	30

41	The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. <i>Rheumatology</i> , 2014 , 53, 1344-6	3.9	14
40	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 492-509	3.4	1487
39	Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 62-8	2.4	467
38	TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes. <i>Journal of Autoimmunity</i> , 2014 , 50, 59-66	15.5	45
37	A1.52 TLR-Dependent XBP1 activation induces an autocrine loop in rheumatoid arthritis synovial fibroblasts. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A22.1-A22	2.4	
36	Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 436	2.8	12
35	The Switch study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 452	2.8	19
34	Creative trial design in RA: optimizing patient outcomes. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 183-94	8.1	12
33	The therapeutic window and treating to target in rheumatoid arthritis. <i>Clinical Medicine</i> , 2013 , 13, 387-90	9.0	1
32	Statins do not influence clinical response and B cell depletion after rituximab treatment in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 463-4	2.4	14
31	Use of gevokizumab for the treatment of Behçet disease. <i>Expert Opinion on Orphan Drugs</i> , 2013 , 1, 755-763	1.1	
30	To switch or not to switch after a poor response to a TNF blocker? It is not only a matter of ACR20 OR ACR50. <i>Autoimmunity Reviews</i> , 2012 , 11, 558-62	13.6	15
29	Relationship between early bone mineral density changes and long-term function and radiographic progression in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 66-70	4.7	15
28	Towards an optimum strategy in rheumatoid arthritis. <i>Lancet, The</i> , 2012 , 379, 1682-4	4.0	4
27	After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?. <i>Postgraduate Medical Journal</i> , 2012 , 88, 482-6	2	16
26	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. <i>Clinical Rheumatology</i> , 2012 , 31, 1005-12	3.9	11
25	Safety of biologics in rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012 , 7, 425-451	4.5	5
24	New therapies in the management of rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011 , 23, 245-51	5.3	54

23	Advances in the development and application of biological therapies for rheumatoid arthritis: review of the latest clinical evidence. <i>Clinical Investigation</i> , 2011 , 1, 557-573		
22	Foot health needs in people with systemic sclerosis: an audit of foot health care provision. <i>Clinical Rheumatology</i> , 2011 , 30, 1611-5	3.9	13
21	Biomarkers in the management of scleroderma: an update. <i>Current Rheumatology Reports</i> , 2011 , 13, 4-12	4.9	20
20	B cell biomarkers of rituximab responses in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3038-47		156
19	Anti-TNF treatment in rheumatoid arthritis. <i>Current Pharmaceutical Design</i> , 2011 , 17, 3141-54	3.3	55
18	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 909-20	2.4	308
17	Reporting of long-term extension studies: lack of consistency calls for consensus. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 886-90	2.4	52
16	Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. <i>Drug, Healthcare and Patient Safety</i> , 2010 , 2, 101-19	1.6	4
15	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 964-75	2.4	1210
14	Sequential use of biologic therapy in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2010 , 22, 321-9	5.3	22
13	Incidence and Risk Factors for Secondary Autoimmune Diseases (AD) After Hematopoietic Stem Cell Transplantation (HSCT) for a Severe Autoimmune Disease-A Retrospective EBMT WP AD Study. <i>Blood</i> , 2010 , 116, 2322-2322	2.2	
12	Costimulation blockade in rheumatic diseases: where we are?. <i>Current Opinion in Rheumatology</i> , 2009 , 21, 244-50	5.3	21
11	Nonresponse to tumor necrosis factor antagonists--is there any point in re-treatment?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 288-9		8
10	Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. <i>Arthritis and Rheumatism</i> , 2004 , 50, 725-8		63
9	Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide. <i>Arthritis and Rheumatism</i> , 2004 , 50, 4072-3		16
8	Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. <i>Journal of Rheumatology</i> , 2003 , 30, 2287-91	4.1	123
7	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , 2002 , 100, 4550-6	2.2	127
6	Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial		4

5	Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	11
4	Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	11
3	Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	5
2	Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial	37
1	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial	65